Company intelligence / Profile preview
SiNON Nano Sciences
- Ownership
- Private
- Development stage
- Other
Overview
SiNON Nano Sciences has developed a patented carbon nanoparticle-based drug delivery platform that enables targeted, controlled release of therapeutics across the blood-brain barrier. The company’s preclinical data suggest improved bioavailability and reduced toxicity for both small molecules and biologics in neurological disease models. As of mid 2025, the company is seed-stage and focused on advancing R&D to determine its positioning as a platform or asset company.
- Therapeutic areas
- NeurologyOncology
- Modalities
- NanoparticleSmall molecule (as payload)Biologic (as payload)DNA (as payload)
- Industry
- Biotech
Drug pipeline
6 assets5 more assets in the full pipeline.
Beyond the preview
Go deeper on SiNON Nano Sciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SiNON Nano Sciences.